CClinicalTrials.gg
TerminatedNCT03409757MicrobiomEisenUpdated Nov 25, 2020

Velphoro and Impact on the Oral Cavity and Gut Microbiome

An observational study in Hyperphosphatemia, sponsored by RWTH Aachen University. Terminated at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-25.

Sponsored by RWTH Aachen University · Observational

Why this study was terminated
Insufficient Patient Recruitment
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
22
Ages
18 Years and older
Sex
All
01

Study summary

This pilot study will be carried out to determine if the regular intake of iron-based Velphoro® by hyperphosphatemia patients influences the microbiome in the oral cavity and/or the gut.

Read the detailed description

The aim of this study is to investigate potential changes in the microbiome of the oral cavity and/or gut in patients with hyperphosphatemia following Velphoro® intake for one month. The principal intention of this study is to assess consequences of Velphoro® medication beyond phosphate control. Adherence to the drug might be compromised by e.g. staining of teeth and biofilm after chewing the product more than recommended. Most likely this is a cosmetic problem only and easy to solve by optimizing oral hygiene. The increased level of iron may have an effect on the gut microbiome which could lead to mild diarrhoea. However, the present study will assess, whether the microbiome both oral and gut changes significantly due to some iron bio-availability, although this is expected to be low with sucroferric oxyhydroxide.

The ultimate goal is to improve patient adherence to the drug and to resolve potential safety concerns.

02

Conditions studied

  • Hyperphosphatemia

Browse trials for

Keywords

  • microbiome
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

hemodialysis patients suffering from hyperphosphatemia and healthy volunteers from the clinical routine in the Department of Operative Dentistry, Periodontology and Preventive Dentistry at the university hospital RWTH Aachen

Inclusion criteria

  • Suffering from hyperphosphatemia
  • Current treatment with a stable dose of a non-iron containing phosphate binder,
  • No or only parenteral iron application
  • Age of ≥ 18 years
  • Written informed consent prior to study participation
  • The subject is willing and able to follow the procedures outlined in the protocol

Control group:

  • Normal renal function
  • No hyperphosphatemia
  • Age- and sex-matched and oral disease status-matched (dental caries and periodontal disease) in comparison to the hyperphosphatemia group
  • Written informed consent prior to study participation
  • The subject is willing and able to follow the procedures outlined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years
  • Currently on oral iron application
  • Antibiotic treatment within the last two months
  • Severe medical events within the last three months
  • Planned surgery for the duration of the sampling
  • Acute/chronic gastrointestinal infections
  • Smokers
  • Oral candidiasis
  • Oral cancer
  • Pregnant and lactating females
  • Haemochromatosis history
  • Committed to an institution by legal or regulatory order
  • Participation in a parallel interventional clinical trial
  • Receipt of an investigational drug within 30 days prior to inclusion into this study
  • The subject is mentally or legally incapacitated

Only for the patient group:

  • Never got any phosphate binder
  • Allergy to Velphoro®
  • Celiac disease or any other chronic inflammatory bowel disease
  • Previous major surgery in the gastrointestinal tract
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
22 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • hemodialysis patients with hyperphosphatemia

    * dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool * Velphoro® medication

    Drug: Velphoro · Other: saliva collection · Other: Supragingival biofilm collection · Other: stool collection · Other: blood collection

  • control group

    - dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool

    Other: saliva collection · Other: Supragingival biofilm collection · Other: stool collection

Interventions

  • DrugVelphoro

    4 weeks

    Also known as: Sucroferric oxyhydroxide

  • Othersaliva collection

    2 samples

  • OtherSupragingival biofilm collection

    2 samples

    Also known as: plaque

  • Otherstool collection

    2 samples

  • Otherblood collection

    2 samples

05

What researchers measure

Primary outcomes

  1. change in relative abundances of iron depending bacterial species within the microbiome from before Velphoro medication to afterwards

    Time frame: 4 weeks

Secondary outcomes

  1. Change of distribution of bacterial species within the microbiome from baseline to after Velphoro medication

    via diversity measure

    Time frame: 4 weeks

06

Study locations

1 site
  • University Hospital of RWTH Aachen, Department of Medicine II
    Aachen, Germany
07

Registry details

Key details

Study ID
NCT03409757
Lead sponsor
RWTH Aachen University
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Feb 28, 2018
Primary completion
Oct 6, 2020
Completion
Oct 6, 2020
Last update
Nov 25, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion